RT Journal Article SR Electronic T1 Neoadjuvant Chemotherapy with Irinotecan and Mitomycin-C for Locally Advanced Squamous Cell Carcinoma of the Uterine Cervix JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 2721 OP 2727 VO 27 IS 4C A1 KATSUJI KOKAWA A1 RYUICHIRO NISHIMURA A1 TUNEO FUJII A1 NAOHIKO UMESAKI YR 2007 UL http://ar.iiarjournals.org/content/27/4C/2721.abstract AB Background: The efficacy and toxicity of combined therapy with irinotecan (CPT-11) and mitomycin-C (MMC) in a neoadjuvant setting were evaluated in patients with locally advanced squamous cell carcinoma (SCC) of the uterine cervix. Patients and Methods: Eligibility included patients with previously untreated cervical carcinoma. CPT-11 (100 mg/m2) was administered on days 1, 8 and 15 intravenously (i.v.), while MMC (10 mg/m2 i.v.) was given on day 1. Survival curves were generated using the Kaplan-Meier method. Results: Among 35 eligible patients, 3 showed a complete response and 27 a partial response, with an overall response rate of 85.7%. No patient showed progressive disease. Thirty-three patients were able to undergo radical surgery after neoadjuvant chemotherapy and only 2 patients (stage IIIb) received radiotherapy without the optimal surgery. The median disease-free survival (DFS) period was 42 months (range 5-73). The median overall survival (OAS) period was 44 months (range 17-74). Two-year DFS and OAS rates were 74.3% and 91.4%, respectively. Of the 58 treatment cycles administered, grade 3 or 4 neutropenia and thrombocytopenia were observed in 50% and 9% of the treatment cycles, respectively. Grade 3 or 4 diarrhea was observed in 6%. Conclusion: Neoadjuvant chemotherapy with CPT-11 and MMC can be effective and well-tolerated against locally advanced SCC of the uterine cervix.